INCIDENCE OF SECOND NEOPLASMS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ANALYSED IN THE FRAME OF INTERNATIONAL RESEARCH PROJECT EUTOS POPULATION BASED STUDY IN RUSSIAN FEDERATION
(Abstract release date: 05/21/15)
EHA Library. Lazareva O. 06/12/15; 102741; PB1756
Disclosure(s): Federal State Budgetary Institution Hematology Research Center, Ministry of Healthcare of Russian FederationScientific Advisory Department for chemotherapy of myeloproliferative disorders
Mrs. Olga Lazareva
Contributions
Contributions
Abstract
Abstract: PB1756
Type: Publication Only
Background
Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) gives hope for a durable disease free survival. Therefore long-term effects of TKI treatment should be studied. A significant event for CML patients (pts) is the development of other tumors, second neoplasms (SN) which can be defined as prior malignancies (pM) if detected before CML diagnosis and second malignancies (sM) which occur after the CML diagnosis during TKI treatment.
Aims
To evaluate the incidence and variants of SN in CML pts treated in clinical practice in Russian Federation (RUS).
Methods
We included 199 CML pts from 7 centers of 6 administrative districts of RUS into RUS part of EUTOS PBS-study. The inclusion criteria were: Ph’/bcr-abl-positive CML diagnosed in 1.10.2009 - 31.12.2012 verified by cytogenetic/ molecular data, age of pts ≥ 18 years (y). Median (Me) age was 50(18- 82)y, sex ratio M/F(%) was 100/99 (50/50)pts. At the time of diagnosis phases of CML were the following: chronic phase (CP) in 187(94%)pts, accelerated phase in 11 (5,5%) pts, blast crisis in 1(0,5%) pts. Me time from diagnosis to imatinib (IM) therapy was 0,6 (0,5-15) months (mo). Pretreatment before IM was the following: hydroxyurea in 99 (50%) pts; IFN-α in 2 (1%) pts. Me follow-up since the CML treatment start was 35.2 (0,5-85)mo (Me for n=192; 7pts were without TKI therapy).
Results
Total rate of sN was 7% (14 of 199 pts). Two of those cases were sM revealed at 22mo (Encephaloma) and 23mo (adenocarcinoma of the colon) after diagnosis of CML, respectively. These 2pts died due to progression of sM after 29 and 32 mo of CML diagnosis respectively. A pM before CML diagnosis was in 6% (12 of 199 pts). Their Me age was 69(33-73)yy, sex ratio (M/F) 4/8pts. The Me time from diagnosis of a pM to CML diagnosis was 61 (28- 429) mo. The pMs were: breast cancer (4/12 of cases), cancer of uterus and ovaries (2/12 of cases), rectal cancer, tumor of the upper third of the shoulder, kidney cancer, prostate cancer, basal cell carcinoma of the eyelid, GIST. Me time of IM therapy was 36 (7- 49)mo. Most of the pts among 12 cases had good results of TKI therapy: 7pts achieved major (4/7) and complete molecular (3/7) response (Me 13 (extr.6–30) mo). Three out of 12 pts with pM in anamnesis died (2 pts not achieved even hematologic response). Pts with sM achieved complete and partial cytogenetic response to 12mo of IM therapy. Mortality in the whole group of 199pts was 15,6% (31cases) and 5 of them (2,5%pts) or 35% (5 of 14 pts) died due to SN progression: 3pts with sM+ 2pts with pM, all 5 were in CP CML.
Summary
Identified cases of SN and CML combination underline a need for understanding the relationship between CML, other malignancies and their therapy. Assosiation of sM annd CML needs deeper analysis during longer observation time.
Keyword(s): Chronic myeloid leukemia, Mortality, Second malignancy, Tyrosine kinase inhibitor
Session topic: Publication Only
Type: Publication Only
Background
Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) gives hope for a durable disease free survival. Therefore long-term effects of TKI treatment should be studied. A significant event for CML patients (pts) is the development of other tumors, second neoplasms (SN) which can be defined as prior malignancies (pM) if detected before CML diagnosis and second malignancies (sM) which occur after the CML diagnosis during TKI treatment.
Aims
To evaluate the incidence and variants of SN in CML pts treated in clinical practice in Russian Federation (RUS).
Methods
We included 199 CML pts from 7 centers of 6 administrative districts of RUS into RUS part of EUTOS PBS-study. The inclusion criteria were: Ph’/bcr-abl-positive CML diagnosed in 1.10.2009 - 31.12.2012 verified by cytogenetic/ molecular data, age of pts ≥ 18 years (y). Median (Me) age was 50(18- 82)y, sex ratio M/F(%) was 100/99 (50/50)pts. At the time of diagnosis phases of CML were the following: chronic phase (CP) in 187(94%)pts, accelerated phase in 11 (5,5%) pts, blast crisis in 1(0,5%) pts. Me time from diagnosis to imatinib (IM) therapy was 0,6 (0,5-15) months (mo). Pretreatment before IM was the following: hydroxyurea in 99 (50%) pts; IFN-α in 2 (1%) pts. Me follow-up since the CML treatment start was 35.2 (0,5-85)mo (Me for n=192; 7pts were without TKI therapy).
Results
Total rate of sN was 7% (14 of 199 pts). Two of those cases were sM revealed at 22mo (Encephaloma) and 23mo (adenocarcinoma of the colon) after diagnosis of CML, respectively. These 2pts died due to progression of sM after 29 and 32 mo of CML diagnosis respectively. A pM before CML diagnosis was in 6% (12 of 199 pts). Their Me age was 69(33-73)yy, sex ratio (M/F) 4/8pts. The Me time from diagnosis of a pM to CML diagnosis was 61 (28- 429) mo. The pMs were: breast cancer (4/12 of cases), cancer of uterus and ovaries (2/12 of cases), rectal cancer, tumor of the upper third of the shoulder, kidney cancer, prostate cancer, basal cell carcinoma of the eyelid, GIST. Me time of IM therapy was 36 (7- 49)mo. Most of the pts among 12 cases had good results of TKI therapy: 7pts achieved major (4/7) and complete molecular (3/7) response (Me 13 (extr.6–30) mo). Three out of 12 pts with pM in anamnesis died (2 pts not achieved even hematologic response). Pts with sM achieved complete and partial cytogenetic response to 12mo of IM therapy. Mortality in the whole group of 199pts was 15,6% (31cases) and 5 of them (2,5%pts) or 35% (5 of 14 pts) died due to SN progression: 3pts with sM+ 2pts with pM, all 5 were in CP CML.
Summary
Identified cases of SN and CML combination underline a need for understanding the relationship between CML, other malignancies and their therapy. Assosiation of sM annd CML needs deeper analysis during longer observation time.
Keyword(s): Chronic myeloid leukemia, Mortality, Second malignancy, Tyrosine kinase inhibitor
Session topic: Publication Only
Abstract: PB1756
Type: Publication Only
Background
Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) gives hope for a durable disease free survival. Therefore long-term effects of TKI treatment should be studied. A significant event for CML patients (pts) is the development of other tumors, second neoplasms (SN) which can be defined as prior malignancies (pM) if detected before CML diagnosis and second malignancies (sM) which occur after the CML diagnosis during TKI treatment.
Aims
To evaluate the incidence and variants of SN in CML pts treated in clinical practice in Russian Federation (RUS).
Methods
We included 199 CML pts from 7 centers of 6 administrative districts of RUS into RUS part of EUTOS PBS-study. The inclusion criteria were: Ph’/bcr-abl-positive CML diagnosed in 1.10.2009 - 31.12.2012 verified by cytogenetic/ molecular data, age of pts ≥ 18 years (y). Median (Me) age was 50(18- 82)y, sex ratio M/F(%) was 100/99 (50/50)pts. At the time of diagnosis phases of CML were the following: chronic phase (CP) in 187(94%)pts, accelerated phase in 11 (5,5%) pts, blast crisis in 1(0,5%) pts. Me time from diagnosis to imatinib (IM) therapy was 0,6 (0,5-15) months (mo). Pretreatment before IM was the following: hydroxyurea in 99 (50%) pts; IFN-α in 2 (1%) pts. Me follow-up since the CML treatment start was 35.2 (0,5-85)mo (Me for n=192; 7pts were without TKI therapy).
Results
Total rate of sN was 7% (14 of 199 pts). Two of those cases were sM revealed at 22mo (Encephaloma) and 23mo (adenocarcinoma of the colon) after diagnosis of CML, respectively. These 2pts died due to progression of sM after 29 and 32 mo of CML diagnosis respectively. A pM before CML diagnosis was in 6% (12 of 199 pts). Their Me age was 69(33-73)yy, sex ratio (M/F) 4/8pts. The Me time from diagnosis of a pM to CML diagnosis was 61 (28- 429) mo. The pMs were: breast cancer (4/12 of cases), cancer of uterus and ovaries (2/12 of cases), rectal cancer, tumor of the upper third of the shoulder, kidney cancer, prostate cancer, basal cell carcinoma of the eyelid, GIST. Me time of IM therapy was 36 (7- 49)mo. Most of the pts among 12 cases had good results of TKI therapy: 7pts achieved major (4/7) and complete molecular (3/7) response (Me 13 (extr.6–30) mo). Three out of 12 pts with pM in anamnesis died (2 pts not achieved even hematologic response). Pts with sM achieved complete and partial cytogenetic response to 12mo of IM therapy. Mortality in the whole group of 199pts was 15,6% (31cases) and 5 of them (2,5%pts) or 35% (5 of 14 pts) died due to SN progression: 3pts with sM+ 2pts with pM, all 5 were in CP CML.
Summary
Identified cases of SN and CML combination underline a need for understanding the relationship between CML, other malignancies and their therapy. Assosiation of sM annd CML needs deeper analysis during longer observation time.
Keyword(s): Chronic myeloid leukemia, Mortality, Second malignancy, Tyrosine kinase inhibitor
Session topic: Publication Only
Type: Publication Only
Background
Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) gives hope for a durable disease free survival. Therefore long-term effects of TKI treatment should be studied. A significant event for CML patients (pts) is the development of other tumors, second neoplasms (SN) which can be defined as prior malignancies (pM) if detected before CML diagnosis and second malignancies (sM) which occur after the CML diagnosis during TKI treatment.
Aims
To evaluate the incidence and variants of SN in CML pts treated in clinical practice in Russian Federation (RUS).
Methods
We included 199 CML pts from 7 centers of 6 administrative districts of RUS into RUS part of EUTOS PBS-study. The inclusion criteria were: Ph’/bcr-abl-positive CML diagnosed in 1.10.2009 - 31.12.2012 verified by cytogenetic/ molecular data, age of pts ≥ 18 years (y). Median (Me) age was 50(18- 82)y, sex ratio M/F(%) was 100/99 (50/50)pts. At the time of diagnosis phases of CML were the following: chronic phase (CP) in 187(94%)pts, accelerated phase in 11 (5,5%) pts, blast crisis in 1(0,5%) pts. Me time from diagnosis to imatinib (IM) therapy was 0,6 (0,5-15) months (mo). Pretreatment before IM was the following: hydroxyurea in 99 (50%) pts; IFN-α in 2 (1%) pts. Me follow-up since the CML treatment start was 35.2 (0,5-85)mo (Me for n=192; 7pts were without TKI therapy).
Results
Total rate of sN was 7% (14 of 199 pts). Two of those cases were sM revealed at 22mo (Encephaloma) and 23mo (adenocarcinoma of the colon) after diagnosis of CML, respectively. These 2pts died due to progression of sM after 29 and 32 mo of CML diagnosis respectively. A pM before CML diagnosis was in 6% (12 of 199 pts). Their Me age was 69(33-73)yy, sex ratio (M/F) 4/8pts. The Me time from diagnosis of a pM to CML diagnosis was 61 (28- 429) mo. The pMs were: breast cancer (4/12 of cases), cancer of uterus and ovaries (2/12 of cases), rectal cancer, tumor of the upper third of the shoulder, kidney cancer, prostate cancer, basal cell carcinoma of the eyelid, GIST. Me time of IM therapy was 36 (7- 49)mo. Most of the pts among 12 cases had good results of TKI therapy: 7pts achieved major (4/7) and complete molecular (3/7) response (Me 13 (extr.6–30) mo). Three out of 12 pts with pM in anamnesis died (2 pts not achieved even hematologic response). Pts with sM achieved complete and partial cytogenetic response to 12mo of IM therapy. Mortality in the whole group of 199pts was 15,6% (31cases) and 5 of them (2,5%pts) or 35% (5 of 14 pts) died due to SN progression: 3pts with sM+ 2pts with pM, all 5 were in CP CML.
Summary
Identified cases of SN and CML combination underline a need for understanding the relationship between CML, other malignancies and their therapy. Assosiation of sM annd CML needs deeper analysis during longer observation time.
Keyword(s): Chronic myeloid leukemia, Mortality, Second malignancy, Tyrosine kinase inhibitor
Session topic: Publication Only
{{ help_message }}
{{filter}}